Negative reactions ofBRAFmutation‐specific immunohistochemistry tonon‐V600Emutations ofBRAF-Reference-Cited by-同舟云学术

Negative reactions ofBRAFmutation‐specific immunohistochemistry tonon‐V600Emutations ofBRAF

Published:2020-01-23 Issue:5 Volume:70 Page:253-261
ISSN:1320-5463
Container-title:Pathology International
language:en
Short-container-title:Pathol Int

Author:

Seto Katsutoshi¹²,Haneda Masataka¹,Masago Katsuhiro¹,Fujita Shiro¹,Kato Seiichi¹,Sasaki Eiichi¹,Hosoda Waki¹,Murakami Yoshiko¹,Kuroda Hiroaki³,Horio Yoshitsugu⁴,Hida Toyoaki⁴,Okubo Kenichi²,Yatabe Yasushi¹^ORCID

Affiliation:

1. Department of Pathology and Molecular DiagnosticsAichi Cancer Center Hospital Aichi Japan

2. Department of Thoracic SurgeryTokyo Medical and Dental University Tokyo Japan

3. Department of Thoracic SurgeryAichi Cancer Center Hospital Aichi Japan

4. Department of Thoracic OncologyAichi Cancer Center Hospital Aichi Japan

Funder

Grants-in-Aid for Scientific Research (B), JSPS

Publisher

Wiley

Subject

General Medicine,Pathology and Forensic Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/pin.12903

Reference55 articles.

1. Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

2. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

3. Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Harboring BRAF Mutations

4. Clinical Characteristics of Patients With Lung Adenocarcinomas HarboringBRAFMutations

5. Clinical next-generation sequencing in patients with non-small cell lung cancer

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. State of the Art of Pathologic and Molecular Testing;Hematology/Oncology Clinics of North America;2023-06

2. Bile duct adenoma and small‐sized small duct type intrahepatic cholangiocarcinoma show distinct differences in genetic alterations, expression of IMP3 and EZH2 and stromal and inflammatory components;Histopathology;2023-05-04

3. Non-small-cell lung cancer: how to manage BRAF-mutated disease;Drugs in Context;2023-05-02

4. Spindle cell neoplasm harboring MAPK signaling pathway gene translocation from the spectrum of <i>NTRK</i>-rearranged spindle cell tumor;Pediatric Hematology/Oncology and Immunopathology;2022-12-26

5. Usefulness of BRAF VE1 immunohistochemistry in non–small cell lung cancers: a multi-institutional study by 15 pathologists in Korea;Journal of Pathology and Translational Medicine;2022-11-15